Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 34

recruiting
3 987
countries
28
conditions
2 109

690 trials match your criteria

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Food allergy

Not recruiting

Study of DBV712 skin patch safety in children aged 1-3 years with peanut allergy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Water For Injection

Hidradenitis

Not recruiting

Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Neuroendocrine carcinoma

Not recruiting

Study of tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab

Myocardial infarction

Not recruiting

Study of Orticumab in Adults with Previous Heart Attack and High Coronary Inflammation Measured by CT Scan

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Orticumab

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Non-small cell lung cancer metastatic

Not recruiting

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Meningococcal infection

Not recruiting

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.